PVs in BRCA2 were identified in 51 out of 204 (25%) individuals overall (19/118 (16%) MBC, 30/80 (37.5%) FBC, 1/3 prostate cancer, 1/3 ovarian cancer). This evidence concerns the gene BRCA2 and ovarian cancer.